Research paper

Comparison of machine learning clustering algorithms for detecting heterogeneity of treatment effect in acute respiratory distress syndrome: A secondary analysis of three randomised controlled trials

Pratik Sinha, Assistant Professor\(^a\)*, Alexandra Spicer\(^b\), Kevin L Delucchi\(^c\), Daniel F McAuley\(^d\),\(^e\), Carolyn S Calfee\(^f\),\(^g\), Matthew M Churpek\(^b\)

\(^a\) Division of Clinical and Translational Research, Division of Critical Care, Department of Anesthesia, Washington University School of Medicine, Saint Louis, MO
\(^b\) Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin
\(^c\) Department of Psychiatry and Behavioral Sciences, University of California, San Francisco; San Francisco, CA
\(^d\) Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast
\(^e\) Regional Intensive Care Unit, Royal Victoria Hospital, Belfast. Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast
\(^f\) Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine; University of California, San Francisco; San Francisco, CA
\(^g\) Department of Anesthesia; University of California, San Francisco; San Francisco, CA

ABSTRACT

Background: Heterogeneity in Acute Respiratory Distress Syndrome (ARDS), as a consequence of its non-specific definition, has led to a multitude of negative randomised controlled trials (RCTs). Investigators have sought to identify heterogeneity of treatment effect (HTE) in RCTs using clustering algorithms. We evaluated the proficiency of several commonly-used machine-learning algorithms to identify clusters where HTE may be detected.

Methods: Five unsupervised: Latent class analysis (LCA), K-means, partition around medoids, hierarchical, and spectral clustering; and four supervised algorithms: model-based recursive partitioning, Causal Forest (CF), and X-learner with Random Forest (XL-RF) and Bayesian Additive Regression Trees were individually applied to three prior ARDS RCTs. Clinical data and research protein biomarkers were used as partitioning variables, with the latter excluded for secondary analyses. For a clustering schema, HTE was evaluated based on the interaction term of treatment group and cluster with day-90 mortality as the dependent variable.

Findings: No single algorithm identified clusters with significant HTE in all three trials. LCA, XL-RF, and CF identified HTE most frequently (2/3 RCTs). Important partitioning variables in the unsupervised approaches were consistent across algorithms and RCTs. In supervised models, important partitioning variables varied between algorithms and across RCTs. In algorithms where clusters demonstrated HTE in the same trial, patients frequently interchanged clusters from treatment-benefit to treatment-harm clusters across algorithms. LCA aside, results from all other algorithms were subject to significant alteration in cluster composition and HTE with random seed change. Removing research biomarkers as partitioning variables greatly reduced the chances of detecting HTE across all algorithms.

Interpretation: Machine-learning algorithms were inconsistent in their abilities to identify clusters with significant HTE. Protein biomarkers were essential in identifying clusters with HTE. Investigations using machine-learning approaches to identify clusters to seek HTE require cautious interpretation.

Funding: NIGMS R35 GM142992 (PS), NHLBI R35 HL140026 (CSC); NIGMS R01 GM123193, Department of Defense W81XWH-21-1-0009, NIA R21 AG068720, NIDA R01 DA051464 (MMC)

© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

ARTICLE INFO

Article History:
Received 14 July 2021
Revised 18 October 2021
Accepted 1 November 2021
Available online 1 December 2021

Keywords:
ARDS
RCTs
Clustering
machine learning
LCA
Heterogeneity of treatment effect

1. Introduction

Randomised controlled trials (RCTs) in the traditional paradigm of evidence-based medicine assume uniform treatment responses among all individuals. It is clear, however, that this assumption is invalid, and becomes more so with increasing heterogeneity in the study population\(^[1,2]\). In critical care, where therapies are frequently...
research in context

Evidence before this study

Heterogeneity subsumed within clinical critical care syndromes, such as acute respiratory distress syndrome (ARDS), has led to a plethora of "negative" clinical trials. To circumnavigate this heterogeneity, investigators are increasingly seeking heterogeneity of treatment effect (HTE) in novel phenotypes/subgroups, with several studies describing approaches to clustering using a multitude of clustering algorithms and data types. The best approach used for identifying clusters where HTE is detectable in secondary analysis of clinical trials, and their comparative benefits and limitations, is not known.

Added value of this study

In this study, we present secondary analyses of three randomised controlled trials (RCTs) of ARDS where we compare nine clustering algorithms (five unsupervised and four supervised) to seek HTE in the identified subgroups. We used a composite of clinical data and protein biomarkers as partitioning variables. Latent class analysis (LCA), causal forest and x-learner with random forest identified HTE in 2/3 of the trials. No single algorithm consistently identified clusters with HTE. LCA aside, most algorithms were highly susceptible to random seed changes leading to alteration of cluster composition and HTE detection. Protein biomarkers were essential partitioning variables for successful detection of HTE in the identified clusters.

Implications of all available evidence

Taken together with the wider literature, our findings reinforce the feasibility of detecting HTE in subgroups identified using machine learning algorithms. The inconsistencies observed with seed changes in some of the machine learning algorithms warrants cautious interpretation of such findings and mandates their prospective validation. It is highly probable that no single algorithm will work in all RCTs and future studies should focus on matching algorithms that are best suited to specific data structures and trial designs.

tested in non-specific clinical syndromes with broad diagnostic criteria, such as sepsis and acute respiratory distress syndrome (ARDS), numerous trials have failed to deliver successful therapies [3,4]. The central premise of precision or personalised medicine is to challenge this paradigm and focus on delivering the right therapies to the right patient by embracing the concept of heterogeneity of treatment effect (HTE). HTE is defined as a non-random, explainable variability in the direction and magnitude of treatment effect [5]. Conceptually, subgroup analyses in RCTs are the most common approach to evaluating HTE. However, performing multiple subgroup analyses in RCTs can result in false discoveries [6,7]. A more predictive, unbiased, and multivariable approach to HTE analyses has been proposed, as it can result in false discoveries [6,7]. A more predictive, unbiased, and multivariable approach to HTE analyses has been proposed, as it avoids the use of single variables with arbitrary cut-offs to determine subgroups [8].

Increasingly, research groups are using machine learning (ML) approaches to identify subgroup within critical care syndromes with the hope of identifying HTE. For example, in ARDS, using latent class analysis (LCA), two subphenotypes of ARDS, with divergent biological features, clinical characteristics and outcomes, have been consistently described across five RCTs [9,12]. In three of these RCTs, the phenotypes showed differential responses to randomised interventions. In sepsis, using k-means clustering, investigators have identified subgroups that showed HTE [13]. Others have proposed using supervised ML algorithms to determine characteristics associated with HTE [14,15]. The optimal approach to finding clusters where HTE is observable, however, remains unknown.

The main objective of this exploratory study was to ascertain the optimal ML algorithm to consistently identify clusters with HTE. Frequently, approaches that combine protein biomarker data with clinical data are used as partitioning variables for subgroup discovery [8]. The importance of protein biomarkers in identifying clusters where HTE is observed remains uncertain. A secondary objective, therefore, was to test whether the detection of HTE was predicated on the inclusion of protein biomarkers as partitioning-variables.

2. Methods

2.1. Overview

The overview of the analysis plan is summarised in Fig. 1. Briefly, the performance of each of the nine clustering algorithm was evaluated independently in secondary analyses of three prior ARDS RCTs. Baseline variables pertaining to demographics, vital signs, ventilatory metrics, clinical laboratory measurements, and research protein biomarkers served as predictors for each algorithm (Table S1). For each algorithm, once patients were classified into clusters, HTE for 90-day mortality was sought, and variable importance for cluster classification was estimated. For secondary analyses, we repeated the above analyses by 1) generating permutations of random seed initiation for relevant algorithms to assess their stability; 2) excluding the protein biomarkers as predictor variables.

2.2. Study Population

Data from three ARDS RCTs conducted by the National Heart, Lung and Blood Institute’s ARDS-Network were used. Permission to conduct these analyses was provided by BioLINCC. ALVEOLI (n=549) tested the efficacy of high positive end-expiratory pressure (PEEP) compared to usual care/lower PEEP [16], FACTT (n=1000) tested the efficacy of conservative versus liberal fluid management strategies [17], SAILS (n=745) tested the efficacy of rosvastatin versus placebo [18]. Specifically, these three trials were selected because the clinical data and biomarker availability, timing of recruitment, and inclusion criteria were relatively uniform across all three RCTs (Table S2). The use of these three RCTs would enable algorithmic performance evaluation in the same clinical syndrome and independent of variances in partitioning variables. In SAILS, in addition to ARDS diagnosis, the inclusion criteria mandated that subjects had a known/suspected infection and met systemic inflammatory response syndrome criteria. Partitioning variables in the clustering algorithms were collected prior to randomisation. Biospecimens for protein biomarkers were collected at enrolment. Assay procedures are described in prior publications [9,11,12].

2.3. Clustering algorithms

The clustering algorithms selected for evaluation were either those commonly described in the medical literature or prominent in the data science literature [19]. The algorithms used for unsupervised clustering were categorised as 1) distance-based: K-means, partitioning around medoids (PAM), hierarchical clustering (HC), and spectral clustering (SC); 2) probability-based: latent class analysis (LCA). These algorithms were implemented agnostic to outcome and treatment group allocation.

All non-normally distributed continuous predictor variables were log-transformed. For algorithms that required complete data, missing values were replaced by single imputation with chained equations (MICE package in R) and the same imputed data was used in all algorithms. A summary of the missing values can be found in Table S3.
Geneity of treatment effect in the clusters was generated for each term (p < 0.05) using the ANOVA likelihood ratio test and a significant interaction term was generated. The interaction term of clusters and treatment group was the independent variable. P-values for the interaction term were generated. For both the supervised and unsupervised approaches, once the optimal number of clusters were identified and observations classified into clusters, HTE was tested using logistic regression models (odds ratio > 1 was associated with harm and < 1 with benefit). Chi-squared test was used to test differences in outcome between the identified clusters.

2.5. Variable importance

To determine the most contributory partitioning variables for cluster identification, for each algorithm, gradient boosted machine models (XGBoost) were trained to classify the identified clusters using the same partitioning-variables as predictors in the model (Table S1). The gain in accuracy in cluster classification with the addition of a variable was computed and cumulatively tallied for each XGBoost model to obtain the relative importance of each variable per algorithm.

2.6. Sensitivity analyses

ML algorithms are subject to instability with perturbations in the random initialisation seed (the starting point from which algorithms are generated). To test the reproducibility of the algorithms, we repeated the above analyses with random seed iterations for all approaches (except LCA, where models were only selected if the maximum likelihood was reproduced in multiple initiation seeds). Nine further runs were performed, each with a new random seed for single imputation and the clustering algorithms. Inter-run similarities in clusters identified across the 10 runs were evaluated using the Adjusted Rand Index (ARI).

Finally, to test the importance of biomarkers for identifying clusters where HTE was observed, we repeated the above analyses by excluding protein biomarkers as predictors.

All clustering approaches, except LCA, were performed on RStudio version 1.1.453 using R version 4.0.1. LCA was performed using MPlus version 8.5.

2.7. Ethics statement

Local institutional review board granted a consent-waiver for the use of de-identified trial data for research purposes.

2.8. Role of funders

Funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
3. Results

The baseline characteristics of the three RCTs and the predictor variables are summarised in Table S1. Among the unsupervised clustering approaches, the number of clusters identified across the cohorts were largely consistent across the three trials. LCA and k-means consistently identified two clusters, whereas PAM and HC identified five clusters (Fig. 2a). Spectral identified two classes in ALVEOLI and SAILS, and five classes in FACTT. The differences in mortality at day-90 between the identified clusters for each algorithm in each trial is summarised in Table 1.

Among the unsupervised methods, pro-inflammatory biomarkers, such as interleukin (IL)-8, IL-6 and soluble tumour-necrosis factor receptor-1 (sTNFR)-1, were prominently and consistently featured as important variables (Fig. 2b). In the supervised approaches, however, no discernible patterns were observable across the three trials. Even within a trial, the pattern of variable importance differed between the supervised algorithms.

Significant HTE interaction with clusters was observed using LCA and X-learner RF clusters in ALVEOLI and FACTT (Fig. 2c). Using CF, significant HTE were observed in FACTT and SAILS. Using K-means, PAM, HC and XL-BART, significant HTE interactions were only observed in one out of the three trials. No significant HTE interactions were observed in clusters identified by either spectral clustering or MOB. In clusters where significant HTE interactions were observed in the same trial, there were substantial differences in patient composition of clusters across the algorithms (Fig. S1). For example, in FACTT, where LCA and XL-BART both identified two clusters with significant HTE, more than half the patients from the increased-mortality cluster in XL-BART crossed over to the lower mortality cluster in LCA and vice versa.

In all trials, with both the supervised and unsupervised algorithms, permutations in random seed initialisation in sequential runs led to several HTE interaction terms no longer being significant despite the same number of clusters being identified. In ALVEOLI, in 10 consecutive runs, significant HTE interactions were observed only in 2 of 10 runs in HC, 3 of 10 runs in XL-RF and 1 of 10 runs in MOB (Fig. S2a). In FACTT, significant HTE was more consistently observed in the supervised approaches (CF and XL-BART; 6 and 4 out of 10 runs respectively) but were inconsistent in the unsupervised approaches (Figure S2b). In SAILS, the findings of HTE were consistent in k-means and XL-BART, however, in CF and XL-RF HTE was observed in only 1 out of 10 runs (Fig. S2c). The mean Adjusted Rand index, a measure of pairwise similarity, for each trial varied widely in
Table 1
Mortality at day 90 in the three trials stratified by the clusters identified by each algorithm. P-values represent chi-squared tests between cluster category and death.

| Trial      | Method     | Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | Cluster 5 | p-value |
|------------|------------|-----------|-----------|-----------|-----------|-----------|---------|
| ALVEOLI    | Unsupervised | LCA       | 20.0      | 46.2      | 30.4      | 37.5      | 21.4    | 0.01    |
|            | K-means    | 23.0      | 43.8      | 13.5      | 33.7      | 18.1      | 0.01    |
|            | PAM        | 20.3      | 24.8      | 13.5      | 33.7      | 18.1      | 0.01    |
|            | HC         | 21.5      | 46.4      | 30.4      | 37.5      | 21.4      | 0.01    |
|            | Spectral   | 22.0      | 43.8      | 13.5      | 33.7      | 18.1      | 0.01    |
|            | MOB        | 25.0      | 25.0      | 25.0      | 25.0      | 25.0      | 0.01    |
|            | CF         | 27.8      | 29.2      | 27.0      | 27.0      | 27.0      | 0.09    |
|            | XL RF      | 19.4      | 35.2      | 35.2      | 35.2      | 35.2      | 0.01    |
|            | XL BART    | 22.1      | 45.1      | 45.1      | 45.1      | 45.1      | 0.01    |
|            | Supervised | MOB       | 25.0      | 32.6      | 32.6      | 32.6      | 0.01    |
|            | K-means    | 24.4      | 41.1      | 41.1      | 41.1      | 41.1      | 0.01    |
|            | PAM        | 14.2      | 25.1      | 31.8      | 38.3      | 52.9      | 0.01    |
|            | HC         | 42.5      | 18.3      | 20.3      | 29.9      | 28.5      | 0.01    |
|            | Spectral   | 18.1      | 30.4      | 36.1      | 23.0      | 47.4      | 0.01    |
|            | Supervised | MOB       | 25.0      | 32.6      | 32.6      | 32.6      | 0.01    |
|            | CF         | 26.9      | 33.6      | 33.6      | 33.6      | 33.6      | 0.06    |
|            | XL RF      | 26.4      | 33.9      | 33.9      | 33.9      | 33.9      | 0.02    |
|            | XL BART    | 32.4      | 23.1      | 23.1      | 23.1      | 23.1      | 0.01    |
| SAILS      | Unsupervised | LCA       | 21.4      | 37.5      | 37.5      | 37.5      | 0.01    |
|            | K-means    | 24.4      | 34.7      | 34.7      | 34.7      | 34.7      | 0.01    |
|            | PAM        | 23.9      | 19.6      | 38.2      | 20.9      | 43.8      | 0.01    |
|            | HC         | 22.4      | 33.3      | 44.0      | 20.0      | 18.6      | 0.01    |
|            | Spectral   | 26.6      | 40.5      | 40.5      | 40.5      | 40.5      | 0.07    |
|            | MOB        | 30.4      | 18.5      | 18.5      | 18.5      | 18.5      | 0.01    |
|            | CF         | 28.3      | 20.8      | 20.8      | 20.8      | 20.8      | 0.16    |
|            | XL RF      | 29.9      | 19.9      | 19.9      | 19.9      | 19.9      | 0.01    |
|            | XL BART    | 25.1      | 31.7      | 31.7      | 31.7      | 31.7      | 0.06    |

ALVEOLI = Assessment of Low Tidal Volume and Elevated End-Expiratory Pressure to Obviate Lung Injury (N = 549), FACTT = Fluids and Catheters Treatment Trial (N = 1000), SAILS = Statins for Acutely Injured Lungs from Sepsis (N = 745). LCA = Latent class analysis, PAM = partitioning around medoids, HC = Hierarchical clustering, MOB = model based recursive partitioning, CF = Causal Forest, XL-RF = X-learner with Random Forest (RF); XL-BART = Bayesian Additive Regression Trees (BART).

each algorithm, and its value was generally low throughout, indicating poor overlap between clusters identified using the various random seed runs for the same algorithm in the same trial cohort (Fig. 3). When the above analyses were repeated with protein biomarkers excluded, as partitioning variables the optimal number of clusters across each algorithm mostly remained the same, albeit, the proportion of observations in each cluster were markedly different (Fig. 4a). Important predictor variables across supervised and unsupervised approaches were more similar, however, there remained notable heterogeneity across the various algorithms (Fig. 4b). Among all the clustering algorithms, without protein biomarker variables, significant HTE interaction was only observed in clusters derived using LCA in the FACTT trial (Fig. 4c).

4. Discussion

In this study, we found wide variations between ML algorithms in their abilities to identify clusters in which significant HTE was observed. Even among algorithms where significant HTE was observed, changing the initiation seed frequently led to the interaction terms no longer being significant. Further, in most clustering algorithms, seed changes also led to heterogeneity in the cluster composition across the different runs. Additionally, as evidenced by the near ubiquitous lack of significant HTE in their absence, research protein biomarkers were critical to identifying clusters with HTE. Taken together, our findings suggest the ability to identify clusters with HTE in RCTs is dependent on the clustering algorithm and partitioning variables used, and no single approach consistently identified clusters with HTE. Further, the inherent algorithmic instability of several approaches mandates caution when interpreting research based on these algorithms.

The relative parity in success of unsupervised and supervised approaches in detecting HTE is unexpected. It is worth reiterating that for unsupervised approaches, outcome data and treatment allocation were excluded from the algorithms. In contrast, supervised approaches were trained directly to detect HTE, and therefore, we anticipated these approaches to out-perform unsupervised ones. Traditionally, unsupervised learning approaches are used for discovering underlying structure in unlabelled data [21,22]. Predominantly, such approaches have been used for biomarker discovery, however, several recent studies have shown that in secondary analyses of RCTs, clusters identified using unsupervised methods can lead to discoveries of differential treatment responses [9,11]. Our findings suggest that there may be validity in using unsupervised approaches to identify clusters with HTE, although some algorithms (e.g., LCA) performed better than others.

Another potential reason for the relative underperformance of the supervised methods in our study was that we coerced coefficients of individual treatment effect (ITE) into dichotomous subgroups to make them comparable to the unsupervised clustering algorithms, a process that is known to cause information loss [23]. Future investigations may need to focus more on maximising ITE, rather than using more traditional approaches of subgroup / cluster HTE analyses, specifically when comparing supervised methods to one another.

Two potential mechanism that can lead to the discovery of HTE have been described, 1) prognostic enrichment: whereby the outcome of interest differs between the identified clusters; 2) predictive enrichment: which seeks to identify patients that are most likely to benefit from a therapy. By definition, given that the models are trained to seek treatment responsive groups, supervised approaches...
are focused towards predictive enrichment. The similarity in outcomes between clusters, and differences in the most important variables, for the supervised algorithms between RCTs observed in our study this. In contrast, the most important variables in the unsupervised approaches that identified clusters with HTE were largely overlapping across RCTs. Which, coupled with the large differences in mortality, is highly suggestive of prognostic enrichment. Prognostic enrichment approaches, while more generalisable across trials, may be non-specific to the intervention.

Our findings were also notable for disparities in the variable importance and cluster composition between algorithms in the same trial. This finding was even notable among clusters where HTE was identifiable in the same trial, suggesting that within populations there may be several different subgroups of patients where HTE is identifiable or that there are a number of patients where their treatment effects are uncertain. In FACTT, among the unsupervised approaches, HTE was detectable using LCA and PAM, and clusters were stratified using IL-8, IL-6, sTNFR-1, and creatinine. Among the supervised approaches, HTE was detectable in CF, X-learner RF and BART, and patient clusters were stratified predominantly using surfactant protein-D, white cell count, intercellular adhesion molecule-1 and minute ventilation. Coupled with the high crossover of patients from the treatment-benefit to treatment-harm cluster and vice versa, our findings suggest that there may be numerous sub-populations where HTE may be detectable within the same trial population. Even when the same computational framework, such as X-learner, was used, the algorithm used to cluster (RF or BART) had a profound impact on the composition of the clusters as evidenced by crossover of patients between clusters identified using the two approaches. These findings further reinforce the necessity to prospectively and externally validate HTE that has been discovered in secondary analyses of RCTs and, as such, this has also been emphasised in a recent multidisciplinary expert panel statement for studies using predictive approaches to seek HTE [24].

The inherent instability of several of the algorithms to random seed perturbations leading to algorithmic instability have been described in other machine-learning approaches [25,26]. However, this phenomenon remains underappreciated in the medical literature. Inadvertently, investigators may misinterpret local maxima as the global maxima (i.e., erroneously accept a suboptimal solution). In algorithms where seed instability is known to be a factor, investigators should demonstrate the robustness of their findings to seed iterations. To that end, it is noteworthy that in LCA, a probabilistic algorithm for determining classes, where the model parameters are subject to statistical assumptions and hypothesis testing is feasible [20], cluster instability to seed perturbations was not a factor. This consistency of subgroup identification may partly explain why LCA was one of the most successful methods at identifying clusters with HTE.

Alongside seed instability, the algorithmic procedures being concealed in a black box, are some of the greatest barriers to real-life clinical implementation of many machine learning algorithms. Black box algorithms generate predictions absent of contemporaneous justification. From the standpoint of traditional medical practices, a lack of understanding of the “how” of the algorithm can be counter-intuitive and a barrier to adopting machine-learning clinical decision-making [27]. The first steps towards implementation of black-box algorithms is to establish its superiority to simpler and/or more intuitive models such as logistic regression or LCA. Next, as with any other modelling, the consistency and robustness of its prediction must be demonstrated in a prospective setting. Once the
utility and validity of such black-box models has been established, efforts need to made towards creating models that accompany concise and clear explanation for the prediction at an individual patient level. The burgeoning field of explainable machine learning endeavours to create such models by either presenting the most important variables driving the prediction or an interpretable translation of the model design or both [28]. [pre-print], [29] Based on these factors, it is incumbent for investigators to determine the plausibility of the explanation for the generated prediction and to establish validity from a scientific / biological standpoint.

Inclusion of research protein biomarkers, such as IL-6, IL-8, sTNFR-1 and surfactant protein-D, were crucial in identifying clusters with HTE. These variables consistently featured among the most important variables driving the prediction or an interpretable translation of the model design or both [28]. The crucial assumption that HTE is present in all three RCTs. However, it is probable this may not be the case. For example, in SAILS, given how infrequently HTE was observed, and that observed HTE was in the context of largely imbalanced cluster sizes, it is conceivable that “true” HTE is not present in this population, however, such a discovery was attributed as unsuccessful in our study. To that end, when translating the findings of HTE analyses in RCTs, the ground truth will seldom, if ever, be known. Therefore, caution must be exercised when designing such studies in order to mitigate bias associated with overfitted models that are specific to the training dataset. When reporting findings of such analyses, measure of robustness should be incorporated, and agreement between multiple orthogonal approaches should be considered to verify the findings in discovering clusters with divergent outcomes and treatment responses in ARDS; how generalisable this finding is to other heterogeneous syndromes remains to be tested.

This study has several strengths. Most notably, we used several machine learning approaches including those that are most widely used and many that are cutting edge. Throughout, we have used objective and automated approaches to selecting the optimal number of clusters. We also evaluated the models in three independent RCTs, adding validity to the findings. This study also has limitations. Subsumed within our primary hypothesis was the assumption that HTE is present in all three RCTs. However, it is probable this may not be the case. For example, in SAILS, given how infrequently HTE was observed, and that observed HTE was in the context of largely imbalanced cluster sizes, it is conceivable that “true” HTE is not present in this population, however, such a discovery was attributed as unsuccessful in our study. To that end, when translating the findings of HTE analyses in RCTs, the ground truth will seldom, if ever, be known. Therefore, caution must be exercised when designing such studies in order to mitigate bias associated with overfitted models that are specific to the training dataset. When reporting findings of such analyses, measure of robustness should be incorporated, and agreement between multiple orthogonal approaches should be considered to verify the findings in discovering clusters with divergent outcomes and treatment responses in ARDS; how generalisable this finding is to other heterogeneous syndromes remains to be tested.
instances where there is uncertainty on the validity of the observed HTE. It is also worth reiterating that, until tested prospectively, the validity of the observed HTE in secondary analyses, such those presented in this study, remains unproven. Additionally, these results are secondary analyses of RCTs of a single clinical syndrome. The performance of these algorithms prospectively and beyond ARDS is unknown. Further, these trials can all be considered as “small” data. It is unclear whether in analyses of larger RCTs, the observed seed instability of the algorithms and critical importance of protein biomarkers remain valid. Based on the available data and the presented analyses, we have not been able to determine which of these algorithms performed best at detecting HTE. It may be that the best algorithm to use may depend on the data structure and size and the quality of the available predictor variables for use in the models. In future studies, we hope to develop an investigative pipeline that may help researchers match their trial data characteristics to the most appropriate algorithm for detecting HTE.

In conclusion, machine learning algorithms were inconsistent in their abilities to identify clusters with significant HTE in secondary analyses of RCTs. Several of the clustering algorithms were susceptible to significant instability with random seed initiations. This stability of algorithms to seed changes should be factored into future evaluation of such studies. In these populations, inclusion of research protein biomarkers as partitioning variables greatly enhanced the ability of the algorithms to identify clusters with HTE. Further studies are needed to establish machine learning pipelines that can robustly and consistently identify either at a subgroup or individual level those that will benefit from therapies in RCTs.

5. Contributors
CSC, MMC, PS and AS contributed to the initial study design. MMC, PS and AS were involved in planning, conduct and reporting of the work described in the study. KLD contributed with study design and analysis of the study. CSC, DFMA and PS contributed to the development of the datasets used for preparation and execution of the studies presented in the manuscript. PS developed the first draft. All authors contributed to the final preparation of the manuscript. PS and MMC accept full responsibility for the work and had access to the data and controlled the decision to publish.

6. Data Sharing
The non-biomarker data were sourced from publicly-available repositories. Requests for sharing of protein biomarker data will be evaluated on an individual basis.

Declaration of Competing Interest
Dr Sinha received institutional grants from the National Institute of Health (NIH), Ms Spicer received institutional grant funding from the NIH and Department of Defense. Prof Delucchi declares no relevant conflicts of interest. Prof McAuley received institutional grants from the NIHR, Innovate UK, MRC, Novavax, Northern Ireland HSC R&D Division, Wellcome Trust; royalties/licenses from Queen’s University Belfast for a patent of novel treatment for inflammatory diseases presented in the manuscript. PS developed the final draft. All authors contributed to the final preparation of the manuscript. PS and MMC accept full responsibility for the work and had access to the data and controlled the decision to publish.

Acknowledgments
We thank all patients who participated in the National Heart Lung and Blood Institute (NHLBI) ARDS Network trials from which data from this study were derived. These include the ALVEOLI, FACTT, and SAILS trials. We acknowledge the contributions of healthcare providers and research staff that enabled the successful completion of these trials. In addition, we thank the contributions of the Biological Specimen and Data Repository Information Coordinating Center of the NHLBI (BIOLINCC) that made the data and biological specimens available to do these studies. This manuscript was prepared using ALVEOLI, ARDSNET, FACTT Research Materials obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the ALVEOLI, ARDSNET, FACTT or the NHLBI. We acknowledge the NIGMS, NHLBI, NIA, and NIDA from the National Institute of Health, and Department of Defense as funders of these studies (NIGMS R35 GM142992 (PS), NHLBI R35 HL140026 (CSC), NIGMS R01 GM123193, Department of Defense W81XWH-21-1-0009, NIA R21 AG068720, NIDA R01 DA051464 (MMC)).

Supplementary materials
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ebiom.2021.103697.

References
[1] Kent DM, Kitsios G. Against pragmatism: on efficacy, effectiveness and the real world. Trials 2009;10:48.
[2] Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 2007;298(10):1209–10.
[3] Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med 2014;20(4):195–203.
[4] Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beilger JR, Mercat A, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers 2019;5(1):18.
[5] Varadhan R, Seeger JD. Estimation and reporting of heterogeneity of treatment effects. In: Velentas P, Dreyer NA, Nourjah P, editors. Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.
[6] Burke JF, Susman JR, Kent DM, Hayward RA. Three simple rules to ensure reasonably credible subgroup analyses. BMJ 2015;351:h5651.
[7] Wallach JD, Sullivan PG, Trepanowski JF, Sainani KL, Steyerberg EW, Ioannidis JP. Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials. JAMA Intern Med 2017;177(4):554–60.
[8] Kent DM, Steyerberg E, van Klaveren D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ 2018;363:k4245.
[9] Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014;2(8):611–20.
[10] Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, et al. Acute respiratory distress syndrome subphenotypes and differential response to statins: secondary analysis of a randomised controlled trial. Lancet Respir Med 2018;6(9):691–8.
[11] Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 2017;195(3):331–8.
[12] Sinha P, Delucchi KL, Thompson BT, McAuley DF, Matthay MA, Calfee CS, et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med 2018;44(11):1859–69.
[13] Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA 2019;321(20):2003–17.
[14] Aytey S, Imbens G. Recursive partitioning for heterogeneous causal effects. Proc Natl Acad Sci U S A 2016;113(27):7353–60.
[15] Wager S, Aytey S. Estimation and inference of heterogeneous treatment effects using random forests. J Am Stat Assoc 2018;113(523):1228–42.
[16] Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004;351(4):327–36.
National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials N. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354(24):2564–75.

National Heart, Lung, and Blood Institute ACTN, Truwit JD, Bernard GR, Steingrub J, Matthay MA, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014;370(23):2191–200.

Andreopoulos B, An A, Wang X, Schroeder M. A roadmap of clustering algorithms: finding a match for a biomedical application. Brief Bioinform 2009;10(3):297–314.

Sinha P, Calfee CS, Delucchi KL. Practitioner’s guide to latent class analysis: methodological considerations and common pitfalls. Crit Care Med 2021;49(1):e63–79.

Greene AC, Giffin KA, Greene CS, Moore JH. Adapting bioinformatics curricula for big data. Brief Bioinform 2016;17(1):43–50.

Sanchez-Pint0 LN, Luo Y, Churpek MM. Big data and data science in critical care. Chest 2018;154(5):1239–48.

Lessov-Schlaggar CN, Rubin JB, Schlaggar BL. The fallacy of univariate solutions to complex systems problems. Front Neurosci 2016;10:267.

Kent DM, Paulus JK, van Klaveren D, D’Agostino R, Goodman S, Hayward R, et al. The predictive approaches to treatment effect heterogeneity (PATH) statement. Ann Intern Med 2020;172(1):35–45.

Feng S, Wallace E, Grissem A, Iyier M, Rodriguez P, Boyd-Graber JL. Pathologies of neural models make interpretation difficult. EMNLP 2018.

McCoy RT, Min J, Linzen T. BERTs of a feather do not generalize together: Large variability in generalization across models with similar test set performance. ArXiv 2020 abs/1911.02969.

Lipton ZC. The Doctor Just Won’t Accept That!2017 November 01, 2017: [arXiv:1711.08037 p.]. Available from: https://ui.adsabs.harvard.edu/abs/2017arXiv171108037L.

Lahav O, Mastronarde N, van der Schaar M. What is Interpretable? Using Machine Learning to Design Interpretable Decision-Support Systems2018 November 01, 2018: [arXiv:1811.10799 p.]. Available from: https://ui.adsabs.harvard.edu/abs/2018arXiv181110799L.

Tonekaboni S, Joshi S, Mcradden MD, Goldenberg A, et al. What clinicians want: contextualizing explainable machine learning for clinical end use. In: Finale D-V, Jin F, Ken J, David K, Rajesh R, Byron W, editors. Proceedings of the 4th Machine Learning for Healthcare Conference; Proceedings of Machine Learning Research: PMLR; 2019. p. 359–80.